BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25596857)

  • 1. Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths.
    Mora S; Puzzovio M; Giacomet V; Fabiano V; Maruca K; Capelli S; Nannini P; Lombardi G; Zuccotti GV
    Endocrine; 2015 Aug; 49(3):783-90. PubMed ID: 25596857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
    Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
    J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of sclerostin and dickkopf-1 in the dramatic alteration in bone mass acquisition in adolescents and young women with recent anorexia nervosa.
    Maïmoun L; Guillaume S; Lefebvre P; Philibert P; Bertet H; Picot MC; Gaspari L; Paris F; Courtet P; Thomas E; Mariano-Goulart D; Bringer J; Renard E; Sultan C
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E582-90. PubMed ID: 24471564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
    Zuccotti G; Viganò A; Gabiano C; Giacomet V; Mignone F; Stucchi S; Manfredini V; Marinacci F; Mora S
    Bone; 2010 Jun; 46(6):1633-8. PubMed ID: 20211284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
    Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
    J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.
    Fazeli PK; Ackerman KE; Pierce L; Guereca G; Bouxsein M; Misra M
    Osteoporos Int; 2013 Sep; 24(9):2433-40. PubMed ID: 23579340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin and Dickkopf-1 in renal osteodystrophy.
    Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin levels and changes in bone metabolism after bariatric surgery.
    Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
    J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis.
    Braz NFT; Rocha NP; Vieira ÉLM; Gomez RS; Barbosa IG; Malheiro OB; Kakehasi AM; Teixeira AL
    Neurol Sci; 2017 Aug; 38(8):1405-1413. PubMed ID: 28488158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of correlation of level of expression of Wnt signaling pathway inhibitors sclerostin and dickkopf-1 with disease activity and severity in rheumatoid arthritis patients.
    Singh A; Gupta MK; Mishra SP
    Drug Discov Ther; 2019; 13(1):22-27. PubMed ID: 30880318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Anastasilakis AD; Kountouras J; Makras P; Papatheodorou A; Kokkoris P; Sakellariou GT; Terpos E
    J Bone Miner Metab; 2016 Jul; 34(4):447-56. PubMed ID: 26056025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.
    Fassio A; Idolazzi L; Viapiana O; Benini C; Vantaggiato E; Bertoldo F; Rossini M; Gatti D
    Clin Rheumatol; 2017 Oct; 36(10):2377-2381. PubMed ID: 28634697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
    Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
    J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.